ClinicalTrials.gg
RecruitingNCT07143318Updated May 26, 2026

First-in-Human Single and Multiple Dose of KLA578-1 for Injection

A Phase 1 interventional study of KLA578-1 for injection and Etopcoxib Tablets in Healthy Volunteers, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single and multiple doses of KLA578-1 for injection in healthy volunteers

Read the detailed description

"The study will be carried out in 2 parts. Part 1: This is a open-label, single ascending dose (SAD) escalation study with a total of 3 dose groups, i.e., Groups 1 to 3. There are a total of 12 volunteers in each group with a similar male to female ratio. Groups 1 and 3 are single-arm study, all volunteers will receive the experimental drug ""KLA578-1 for Injection"" ; Group 2 is a randomized, two-treatment, two-period, crossover study, 12 volunteers will be randomized to TR sequence or RT sequence with 6 volunteers in each sequence. The experimental drug ""KLA578-1 for injection"" will be administered in the TR sequence of Period 1, the control drug ""Etopcoxib Tablets"" will be administered to the RT sequence. After 7 days of washing, the control drug ""Etocoxib Tablets"" will be administered in the TR sequence, and the experimental drug ""KLA578-1 for Injection"" will be administered in the RT sequence.

Part 2: This is a open-label, single-arm multiple dose study. A dose group is temporarily set up, with a total of 12 volunteers enrolled, and the male-to-female ratio will be similar. Volunteers will receive the experimental drug ""KLA578-1 for Injection"" 120 mg once daily (every 24 h ± 2 min with reference to the dosing time on D1) under fasting conditions (fasting for at least 10 hours) from D1 to D5; Drinking water is prohibited from 1 h before each dose to 1 h postdose, and fasted within 4 hours after dosing on D1 and D5."

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy
03

In context

Lead sponsor

Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Health Volunteers (Age: 18\~45 years);
  2. Body Weight: Male≥50.0kg, Female≥45.0kg; 19.0 ≤≤ 26.0;
  3. There were no abnormalities in physical examination, vital signs, 12-lead , laboratory tests;
  4. Heart rate ≥ 60 bpm and pulse ≥ 60 beats/min.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or Drug ;
  2. Medical History;
  3. Gastrointestinal ulcers or gastrointestinal bleeding;
  4. History of any surgery within 4 weeks;
  5. History of any Medication within 14 days;
  6. History of any inducers or inhibitors of major CYP450 enzymes within 30 days;
  7. History of any clinical study within 3 months;
  8. History of any vaccine within 1 month;
  9. History of any drug abuse;
  10. Tablet dysphagia;
  11. Needle sickness, Hematosickness;
  12. Massive blood loss (> 200 mL) in the past 3 months;
  13. Female volunteers are pregnant or lactating;
  14. History of unprotected sex within 2 weeks;
  15. Special requirements for diet;
  16. Heavy smoker ( more than 3 cigarettes/day) within 3 months;
  17. History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months;
  18. Heavy caffeine intake;
  19. History of grapefruit, xanthine-rich foods intake within 7 days;
  20. Positive alcohol test;
  21. Positive drugs of abuse test result.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    KLA578-1 60mg

    12 volunteers receive KLA578-1 for injection 60mg

    Drug: KLA578-1 for injection

  • Active comparator
    KLA578-1 120mg

    Period 1, 6 volunteers receive KLA578-1 for injection 120mg → 6 volunteers receive Etopcoxib Tablets 120mg; Period 2, 6 volunteers receive Etopcoxib Tablets 120mg → 6 volunteers receive KLA578-1 for injection 120mg

    Drug: KLA578-1 for injection · Drug: Etopcoxib Tablets

  • Experimental
    KLA578-1 240mg

    12 volunteers receive KLA578-1 for injection 240mg

    Drug: KLA578-1 for injection

  • Experimental
    multiple doses of KLA578-1 for injection

    12 volunteers receive KLA578-1 for injection 120mg over 5 consecutive days.

    Drug: KLA578-1 for injection

Interventions

  • DrugKLA578-1 for injection

    Intravenous injection, single dose

  • DrugEtopcoxib Tablets

    P.O., single dose

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: Up to day 13

Secondary outcomes

  1. PK parameter Cmax

    Maximum peak plasma concentration (Cmax) after single dose and in a steady state after multiple doses

    Time frame: single dose:up to Day 6 ; multiple doses: up to Day 8

  2. PK parameter Tmax

    Time of Cmax (Tmax) after single dose and in a steady state after multiple doses

    Time frame: single dose:up to Day 6 ; multiple doses: up to Day 8

  3. PK parameter Cmin,ss

    The trough concentration observed during the drug administration interval in a steady state (Cmin,ss) after multiple doses

    Time frame: multiple doses: up to Day 1

  4. PK parameter AUC0-t

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" after single dose and in a steady state after multiple doses

    Time frame: single dose:up to Day 6 ; multiple doses: up to Day 8

  5. PK parameter AUC0-∞

    AUC from time zero to infinity (AUC0-∞) after single dose and in a steady state after multiple doses

    Time frame: single dose:up to Day 6 ; multiple doses: up to Day 8

  6. PK parameter AUCtau,ss

    AUC for the drug administration interval in a steady state (AUCtau,ss) after multiple doses

    Time frame: multiple doses: up to Day 1

  7. PK parameter t1/2

    Terminal-phase elimination half-life (t1/2) after single dose and in a steady state after multiple doses

    Time frame: single dose:up to Day 6 ; multiple doses: up to Day 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 27, 2025
StartActual
Jun 5, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143318
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Jun 5, 2025
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
May 26, 2026

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion